rAAV CLN1 Gene Delivery for CNS Targeting in Batten Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are currently no effective therapies to reverse the symptoms of CLN1-Batten Disease, a severe neurodegenerative disorder caused by mutations in the CLN1 gene, which leads to worsening vision, movement, and thinking ability issues, with seizures sometimes managed only by antiseizure drugs.
Innovation Solution
The use of recombinant adeno-associated virus (rAAV) vectors to deliver a CLN1 polynucleotide, encoding the CLN1 polypeptide, to the central nervous system, specifically targeting nerve and glial cells in the brain and spinal cord, via intrathecal, intracerebroventricular, or intravenous routes, using self-complementary or single-stranded genomes and various AAV serotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant AAV vectors are used to deliver CLN1 polynucleotide to the central nervous system, then therapeutic benefits are achieved by increasing clearance of lysosomal storage material and reducing disease progression, but the complexity of the treatment protocol increases due to multiple administration routes and vector types
Solution Approach 1:
The patent employs multiple AAV serotypes (AAV1, AAV2, AAV5, AAV8, AAV9, AAVrh74) that can all deliver the CLN1 polynucleotide to the central nervous system through different administration routes (intrathecal, intracerebroventricular, intravenous). This multi-functionality approach ensures therapeutic effectiveness while providing flexibility to select from various vector and administration options based on patient-specific factors.
Solution Approach 2:
The patent utilizes different genome types (self-complementary and single-stranded) and multiple AAV serotypes with varying tropism and transduction efficiencies. By changing parameters such as vector serotype, genome type, and administration route, the treatment can be optimized for individual patients while maintaining therapeutic effectiveness.
2Productivity
If multiple AAV serotypes and administration routes are utilized to ensure effective delivery, then gene delivery efficiency to the central nervous system is improved, but the ease of operation decreases due to the need to select and optimize among multiple options
Solution Approach 1:
The patent divides the treatment approach into distinct segments: multiple AAV serotypes (AAV1, AAV2, AAV5, AAV8, AAV9, AAVrh74), different genome types (self-complementary, single-stranded), and various administration routes (intrathecal, intracerebroventricular, intravenous). This segmentation allows clinicians to select and optimize individual components based on patient needs, improving delivery efficiency while maintaining operational flexibility.
Solution Approach 2:
The patent uses AAV vectors as intermediary carriers to deliver the CLN1 polynucleotide to target cells in the central nervous system. Different AAV serotypes serve as intermediaries with varying abilities to cross the blood-brain barrier and transduce specific cell types, thereby improving gene delivery efficiency while allowing selection based on operational considerations.
3Productivity
If self-complementary or single-stranded AAV genomes are used to deliver the CLN1 polynucleotide, then transduction efficiency is improved, but the manufacturing complexity increases due to the need to produce and characterize different genome types
Solution Approach 1:
The patent employs different genome types (self-complementary and single-stranded) and multiple AAV serotypes as variable parameters to optimize transduction efficiency for different clinical scenarios. The manufacturing process can be adjusted to produce the selected genome type, allowing flexibility in balancing transduction efficiency with manufacturing considerations based on patient-specific needs.
Data Source
AI summary
The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of a neuronal ceroid lipofuscinosis neuronal 1 (CLN1) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for CLN1 gene therapy of the neuronal ceroid lipofuscinosis CLN1-Batten Disease.